{"id":122,"date":"2018-01-19T04:30:00","date_gmt":"2018-01-18T23:30:00","guid":{"rendered":"http:\/\/www.policymed.com\/christmas-comes-early-the-fcpa-pilot-program-made-permanent\/"},"modified":"2018-05-04T00:27:24","modified_gmt":"2018-05-03T19:27:24","slug":"christmas-comes-early-the-fcpa-pilot-program-made-permanent","status":"publish","type":"post","link":"https:\/\/www.policymed.com\/2018\/01\/christmas-comes-early-the-fcpa-pilot-program-made-permanent.html","title":{"rendered":"Christmas Comes Early &#8211; The FCPA Pilot Program Made Permanent"},"content":{"rendered":"<p><em><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">When we first introduced the FCPA Pilot Program in the June 2016 issue, we noted the uncertainties of outcomes for companies who voluntarily self-disclose potential violations. On\u00a0<\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">November 29, 2017, Deputy Attorney General Rod Rosenstein announced that the US Department of Justice (DOJ) had made the FCPA Pilot Program permanent. This article will review some of the key highlights outlined by the DOJ and some considerations for compliance professionals.<\/span><\/em><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">The heat is on life science companies. Since 2013, there have been 25 Foreign Corruption Practices Act (\u201cFCPA\u201d) matters involving life science companies, 13 of which occurred in\u00a0the last two years. Although life science companies have not been immune to FCPA investigations in the past, the statement of Acting Chief of the U.S. Department of Justice (\u201cDOJ\u201d) Fraud Section, Sandra Moser in August was loud and clear &#8211; the DOJ would be increasing its enforcement efforts of healthcare related companies.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">We reviewed the outcomes of the FCPA Pilot Program (\u201cPilot Program\u201d) in the September 2017 issue of the Update, examining the benefits of self-disclosure under the program. Now, a <span style=\"color: #b9b9b9;\">y<span style=\"background-color: #ffffff;\">ear since its inception, the DOJ has announced that the Pilot Program will now be permanent.<\/span><\/span><\/span><\/p>\n<div style=\"height: 30px; background: #336699; width: 750px; padding: 10px 0px 4px 20px; font-family: Verdana,sans-serif; font-size: 1.2em; color: white;\">To Read the Full Story, <a style=\"color: white;\" href=\"http:\/\/www.lifescicompliance.com\/subscription-options\/\"><strong>Subscribe<\/strong><\/a>, <strong>Download a <a style=\"color: white;\" href=\"https:\/\/www.lifescicompliance.com\/sample-issue-contact-information\/\">Sample Issue<\/a><\/strong>, or <a style=\"color: white;\" href=\"https:\/\/www.lifescicompliance.com\/login\/\"><strong>Sign In<\/strong><\/a><\/div>\n<div style=\"width: 770px;\"><a href=\"http:\/\/www.lifescicompliance.com\"><img decoding=\"async\" class=\"asset asset-image at-xid-6a00e5520572bb883401b8d1c8ad6d970c image-full img-responsive\" style=\"width: 770px;\" title=\"PM_LSCU_Box\" src=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b8d1c8ad6d970c-800wi\" alt=\"PM_LSCU_Box\" height=\"253\" border=\"0\" \/><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>When we first introduced the FCPA Pilot Program in the June 2016 issue, we noted the uncertainties of outcomes for companies who voluntarily self-disclose potential violations. On\u00a0November 29, 2017, Deputy Attorney General Rod Rosenstein announced that the US Department of Justice (DOJ) had made the FCPA Pilot Program permanent. This article will review some of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3545,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,41],"tags":[1101],"class_list":["post-122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fcpa","category-life-science-compliance-update","tag-new"],"_links":{"self":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/122"}],"collection":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/comments?post=122"}],"version-history":[{"count":1,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/122\/revisions"}],"predecessor-version":[{"id":3547,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/122\/revisions\/3547"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media\/3545"}],"wp:attachment":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media?parent=122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/categories?post=122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/tags?post=122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}